4-(3,4-Dimethylphenyl)-1,3-thiazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3,4-Dimethylphenyl)-1,3-thiazole
• 化学式: C₁₁H₁₁NS
• 分子量: 189.28
• InChiKey: DDCJFNVSCDPQMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• METHODS FOR TREATING VASCULAR LEAK SYNDROME
  申请人：Shalwitz Robert

  公开号：US20140179693A1

  公开（公告）日：2014-06-26

  Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, inflammatory bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells and/or preventing the proliferation of carcinoma cells via spreading due to vascular leakage.

  揭示了治疗血管渗漏综合征的方法。进一步揭示了治疗由炎症性疾病引起的血管渗漏的方法，包括败血症、红斑狼疮、炎症性肠病等。还揭示了治疗肾细胞癌和黑色素瘤的方法。更进一步揭示了通过血管渗漏引起的恶性细胞转移的方法，以及预防癌细胞通过扩散而蔓延的方法。
• Human protein tyrosine phosphatase inhibitors an methods of use
  申请人：Gray Lyle Jeffrey

  公开号：US20080108631A1

  公开（公告）日：2008-05-08

  The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

  本公开涉及有效作为人类蛋白酪氨酸磷酸酶β（HPTP-β）抑制剂的化合物，从而调节血管生成。本公开进一步涉及包含所述人类蛋白酪氨酸磷酸酶β（HPTP-β）抑制剂的组合物，以及用于调节血管生成的方法。
• COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
  申请人：Shalwitz Robert

  公开号：US20120128625A1

  公开（公告）日：2012-05-24

  Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.

  本发明揭示了预防癌细胞转移的方法。所揭示的化合物可用于预防肿瘤或其他类型的癌细胞扩散。
• COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
  申请人：Peters Kevin Gene

  公开号：US20120129847A1

  公开（公告）日：2012-05-24

  Disclosed are methods for the treatment of diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like.

  本发明公开了治疗眼部疾病或病症的方法，特别是视网膜病变、眼部水肿和眼部新生血管形成。这些疾病或病症的非限制性示例包括糖尿病性黄斑水肿、老年性黄斑变性（湿性）、脉络膜新生血管形成、糖尿病性视网膜病变、视网膜静脉阻塞（中央或分支）、眼部创伤、手术引起的水肿、手术引起的新生血管形成、囊样黄斑水肿、眼部缺血、葡萄膜炎等。
• COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES
  申请人：HYDRA BIOSCIENCES, INC

  公开号：US20130303521A1

  公开（公告）日：2013-11-14

  Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.

  本文描述了用于治疗因暴露于化学战剂而引起的损伤的化合物和组合物。